These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 25157763)
1. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763 [TBL] [Abstract][Full Text] [Related]
2. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133 [TBL] [Abstract][Full Text] [Related]
3. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685 [TBL] [Abstract][Full Text] [Related]
4. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway. Zhang SC; Cai WS; Zhang Y; Jiang KL; Zhang KR; Wang WL Cancer Lett; 2012 Dec; 325(2):227-37. PubMed ID: 22796607 [TBL] [Abstract][Full Text] [Related]
5. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196 [TBL] [Abstract][Full Text] [Related]
6. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484 [TBL] [Abstract][Full Text] [Related]
7. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms]. Xia M; Meng G; Dong J Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041 [TBL] [Abstract][Full Text] [Related]
8. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872 [TBL] [Abstract][Full Text] [Related]
9. A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells. Fujiyuki T; Yoneda M; Amagai Y; Obayashi K; Ikeda F; Shoji K; Murakami Y; Sato H; Kai C Oncotarget; 2015 Sep; 6(28):24895-903. PubMed ID: 26317644 [TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950 [TBL] [Abstract][Full Text] [Related]
11. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271 [TBL] [Abstract][Full Text] [Related]
12. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818 [TBL] [Abstract][Full Text] [Related]
13. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma. De A; Jacobson BA; Peterson MS; Jay-Dixon J; Kratzke MG; Sadiq AA; Patel MR; Kratzke RA Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477 [TBL] [Abstract][Full Text] [Related]
14. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains. Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634 [TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422 [TBL] [Abstract][Full Text] [Related]
17. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267 [TBL] [Abstract][Full Text] [Related]
18. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum. Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834 [TBL] [Abstract][Full Text] [Related]
19. Wild-type measles virus with the hemagglutinin protein of the edmonston vaccine strain retains wild-type tropism in macaques. Takeuchi K; Nagata N; Kato SI; Ami Y; Suzaki Y; Suzuki T; Sato Y; Tsunetsugu-Yokota Y; Mori K; Van Nguyen N; Kimura H; Nagata K J Virol; 2012 Mar; 86(6):3027-37. PubMed ID: 22238320 [TBL] [Abstract][Full Text] [Related]
20. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Baldo A; Galanis E; Tangy F; Herman P Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]